By Prakhar Srivastava (Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 ...

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs. Novo Nordisk has asked the FDA to block compounders from making versions ...

Already-listed Enliven Therapeutics, which develops small-molecule kinase inhibitors for cancer, revealed plans to raise $90 million through a private investment in public equity (PIPE ...